MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ALL-ORDS | ALL-TECH

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.04

23 Sep
2021

0.040

OPEN

$1.00

4.00%

HIGH

$1.04

149,756

LOW

$1.00

TARGET
$1.56 50.0% upside
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . SHL . VRT . HLA . PSQ . SIL . PKS . ONT . DOC . NVL . AHX . ALC . ACL .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx - 4.0 - 1.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx-4.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx19.0 M
Book Value Per Share xxxxxxxxxxxxxxx24.5
Net Operating Cash Flow xxxxxxxxxxxxxxx1.5 M
Net Profit Margin xxxxxxxxxxxxxxx-49.18 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx-13.50 %
Return on Equity xxxxxxxxxxxxxxx-16.80 %
Return on Total Capital xxxxxxxxxxxxxxx-18.23 %
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.52 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1.4 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

24/08/2021

1

Add

$1.56

50.00%

Morgans assesses an in-line result for FY21, which included a record sales order book and further R&D spend (28% of revenue) into new product development. Management expects to be earnings (EBITDA) positive for FY22.

While the share price has been weak over recent months, the analyst expects the result will provide confidence to the market of significant revenue growth in the coming years. Morgans retains its Add rating and $1.56 target price.

Management also noted that the previously announced revenue target of $27m for 2021 is on-track.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -1.00 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of 2.00 cents.

M7T STOCK CHART